GALTGALECTIN THERAPEUTICS INC

Nasdaq galectintherapeutics.com


$ 2.31 $ 0.00 (0 %)    

Friday, 23-Aug-2024 15:59:48 EDT
QQQ $ 479.76 $ 5.15 (1.08 %)
DIA $ 411.97 $ 4.35 (1.07 %)
SPY $ 562.00 $ 5.91 (1.06 %)
TLT $ 98.37 $ 0.64 (0.65 %)
GLD $ 231.99 $ 2.65 (1.16 %)
$ 2.31
$ 2.29 x 100
-- x --
-- - --
$ 1.56 - $ 4.27
107,228
na
143.86M
$ 0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 03-29-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-30-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-31-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-17-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-16-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-09-2019 06-30-2019 10-Q
22 05-10-2019 03-31-2019 10-Q
23 03-06-2019 12-31-2018 10-K
24 11-13-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
26 05-11-2018 03-31-2018 10-Q
27 03-29-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-14-2017 06-30-2017 10-Q
30 05-15-2017 03-31-2017 10-Q
31 03-28-2017 12-31-2016 10-K
32 11-08-2016 09-30-2016 10-Q
33 08-09-2016 06-30-2016 10-Q
34 05-10-2016 03-31-2016 10-Q
35 03-15-2016 12-31-2015 10-K
36 11-09-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 05-11-2015 03-31-2015 10-Q
39 03-18-2015 12-31-2014 10-K
40 11-10-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-galectin-therapeutics-maintains-11-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price ta...

 galectin-therapeutics-q2-eps-020-misses-016-estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate ...

 hc-wainwright--co-reiterates-buy-on-galectin-therapeutics-maintains-11-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price ta...

 galectin-therapeutics-highlights-outcome-of-fifth-data-and-safety-monitoring-board-meeting-for-navigate-phase-2b3-study

Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE...

 hc-wainwright--co-reiterates-buy-on-galectin-therapeutics-maintains-11-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price ta...

 galectin-therapeutics-q3-eps-024-misses-016-estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate ...

 galectin-therapeutics-reports-the-outcome-of-the-fourth-data-and-safety-monitoring-board-meeting-for-navigate-its-seamless-adaptive-phase-2b3-study-of-belapectin-in-patients-with-portal-hypertension-caused-by-non-alcoholic-steatohepatitis-live

Galectin Therapeutics, Inc.

 galectin-therapeutics-to-present-update-on-its-belapectin-liver-cirrhosis-program-at-the-20th-edition-of-discovery-on-target-meeting-in-boston-september-25-28-2023

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced it wil...

 hc-wainwright--co-reiterates-buy-on-galectin-therapeutics-maintains-11-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price ta...

 galectin-therapeutics-q2-eps-015-beats-021-estimate

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of...

 galectin-therapeutics-and-3-other-stocks-under-2-insiders-are-buying

The Dow Jones closed higher by more than 150 points on Thursday. When insiders purchase or sell shares, it indicates their conf...

 hc-wainwright--co-reiterates-buy-on-galectin-therapeutics-maintains-11-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price ta...

 galectin-therapeutics-q1-eps-019-beats-021-estimate-the-company-had-178-million-of-cash-and-cash-equivalents-and-expects-that-it-will-require-more-cash-to-fund-operations-after-december-31-2024

Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION